Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WelChol Long-Term Safety Extension in Type 2 Diabetes
NCT00151762Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2004
- Primary completion
- Jul 2007
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of colesevelam in type 2 diabetes mellitus (T2DM), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Safety and Tolerability. Started Dec 2004; status: completed.
02
Drugs
colesevelam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00151762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151762.